Better Therapeutics Statistics
Share Statistics
Better Therapeutics has 54.52M shares outstanding. The number of shares has increased by 9.33% in one year.
| Shares Outstanding | 54.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 24.48M |
| Failed to Deliver (FTD) Shares | 400 |
| FTD / Avg. Volume | 1.79% |
Short Selling Information
The latest short interest is 2.13M, so 3.9% of the outstanding shares have been sold short.
| Short Interest | 2.13M |
| Short % of Shares Out | 3.9% |
| Short % of Float | 8.68% |
| Short Ratio (days to cover) | 0.94 |
Valuation Ratios
The PE ratio is -0.66 and the forward PE ratio is null.
| PE Ratio | -0.66 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | -29.09 |
| P/FCF Ratio | -0.87 |
| PEG Ratio | n/a |
Enterprise Valuation
Better Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of -16.55.
| Current Ratio | 1.37 |
| Quick Ratio | 1.37 |
| Debt / Equity | -16.55 |
| Total Debt / Capitalization | 106.43 |
| Cash Flow / Debt | -1.94 |
| Interest Coverage | -25.66 |
Financial Efficiency
Return on equity (ROE) is 44.23% and return on capital (ROIC) is -273.72%.
| Return on Equity (ROE) | 44.23% |
| Return on Assets (ROA) | -1.73% |
| Return on Capital (ROIC) | -273.72% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -736.30K |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 7.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.89, so Better Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.89 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 47.99 |
| Average Volume (20 Days) | 22.39K |
Income Statement
In the last 12 months, Better Therapeutics had revenue of $0 and earned -$39.76M in profits. Earnings per share was $-1.69.
| Revenue | 0 |
| Gross Profit | -2.73M |
| Operating Income | -38.26M |
| Net Income | -39.76M |
| EBITDA | -38.26M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.69 |
Balance Sheet
The company has $15.74M in cash and $14.88M in debt, giving a net cash position of $860.00K.
| Cash & Cash Equivalents | 15.74M |
| Total Debt | 14.88M |
| Net Cash | 860.00K |
| Retained Earnings | -111.50M |
| Total Assets | 10.72M |
| Working Capital | -5.59M |
Cash Flow
In the last 12 months, operating cash flow was -$28.93M and capital expenditures -$1.18M, giving a free cash flow of -$30.11M.
| Operating Cash Flow | -28.93M |
| Capital Expenditures | -1.18M |
| Free Cash Flow | -30.11M |
| FCF Per Share | -1.28 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BTTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | -552274.39% |
Analyst Forecast
Currently there are no analyst rating for BTTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -27.28 |
| Piotroski F-Score | 2 |